Efficacy and safety of latanoprost in eyes with uveitic glaucoma

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 6, 2009, Pages 775-780

  Markomichelakis, Nikos N ^a   Kostakou, Agori ^b   Halkiadakis, Ioannis ^b   Chalkidou, Sonia ^b   Papakonstantinou, Dimitrios ^c   Georgopoulos, Gerasimos ^c  

^a KAT HOSPITAL   (Greece)

^b Central Clinic of Athens   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anterior uveitis; Dorzolamide; Glaucoma; Latanoprost; Timolol

Indexed keywords

BRIMONIDINE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; STEROID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; EYE SURGERY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETINA MACULA EDEMA; UVEITIS; VISUAL ACUITY;

ADULT; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RECURRENCE; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; UVEITIS, ANTERIOR; UVEITIS, INTERMEDIATE; VISUAL ACUITY;

EID: 67349125142     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1036-3     Document Type: Article

References (30)

1. Kok H, Barton K (2002) Uveitic glaucoma. Ophthalmol Clin North Am 15:375-387, doi: 10.1016/S0896-1549(02)00028-7
2. Moorthy RS, Mermoud A, Baerveldt G, Minckler DS, Lee PP, Rao NA (1997) Glaucoma associated with uveitis. Surv Ophthalmol 41:361-394, doi: 10.1016/S0039-6257(97)00006-4
3. Papadaki TG, Zacharopoulos IP, Pasquale LR, Christen WB, Netland PA, Foster CS (2007) Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol 144:62-69, doi: 10.1016/ j.ajo.2007.03.013
4. Eakins KE (1977) Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res 25:483-498, doi: 10.1016/ S0014-4835(77)80043-2
5. Ziai N, Dolan JW, Kacere RD, Brubaker RF (1993) The effects on aqueous dynamics of PhXA41, a new prostaglandin in normal and ocular hypertensive human eyes. Arch Ophthalmol 111:1351-1358
6. Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP (2008) The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22:179-183, doi: 10.1038/sj.eye.6702542
7. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R (1998) Anterior uveitis associated with latanoprost. Am J Ophthalmol 126:37-41, doi: 10.1016/ S0002-9394(98)00071-3
8. Warwar RE, Bullock JD, Ballal D (1998) Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105:263-268, doi: 10.1016/S0161-6420(98)92977-3
9. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC (1999) Latanoprost 0.005% and anterior uveitis. Acta Ophthalmol Scand 77:668-672, doi: 10.1034/j.1600-0420.1999.770612.x
10. Sacca S, Pascotto A, Siniscalchi C (2001) Ocular complications of latanoprost in uveitic glaucoma: Three case reports. J Ocul Pharmacol Ther 17:107-113, doi: 10.1089/10807680151125393
11. Sung V, Barton K (2004) Management of inflammatory glaucomas. Curr Opin Ophthalmol 15:136-140, doi: 10.1097/00055735-200404000-00014
12. Schumer RA, Camras CB, Mandahl AK (2002) Putative side effects of prostaglandin analogs. Surv Ophthalmol 47(Suppl 1):S219, doi: 10.1016/ S0039-6257(02)00328-4
13. Alm A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with Timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752
14. Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 103:138-147
15. Watson P, Stjernschantz J (1996) A six-month, randomized, double-masked studycomparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126-137
16. Mishima HK, Masuda K, Kitazawa Y (1996) A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 114:929-932
17. Miyake K, Ibaraki N (2002) Prostaglandins and cystoid macular edema. Surv Ophthalmol 47(Suppl 1):S203-S218, doi: 10.1016/S0039-6257(02)00294-1
18. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA (2005) Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: Combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 21:242-249, doi: 10.1089/jop.2005.21.242
19. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA (2004) COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: Results from two randomized clinical trials. Acta Ophthalmol Scand 82:42-48, doi: 10.1046/ j.1600-0420.2004.0205.x
20. Honrubia FM, Larsson LI, Spiegel D (2002) European latanoprost study group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 80:635-641, doi: 10.1034/j.1600-0420.2002.800615.x
21. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop. Am J Ophthalmol 140:509-516, doi: 10.1016/ j.ajo.2005.01.035
22. Markomichelakis NN, Halkiadakis I, Pantelia E, Georgalas E, Chrysanthi K, Theodossiadis P, Moschos M, Theodossiadis G, Kouvatseas G (2007) Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm 15(2):71-79, doi: 10.1080/09273940701244509
23. Chang JH, McCluskey P, Missotten T, Ferrante P, Jalaludin B, Lightman S (2008) Use of ocular hypotensive prostaglandin analogues in patients with uveitis: Does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol 92:916-921, doi: 10.1136/bjo.2007.131037
24. Wand M, Gilbert CM, Liesegang TJ (1999) Latanoprost and herpes simplex keratitis. Am J Ophthalmol 127:602-604, doi: 10.1016/ S0002-9394(99)00050-1
25. Ekatomatis P (2001) Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol 85:1008-1009, doi: 10.1136/bjo.85.8.1007a
26. Morales J, Shihab ZM, Brown SM, Hodges MR (2001) Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol 132:114-116, doi: 10.1016/S0002-9394(01)01012-1
27. Herpetic Eye Disease Study Group (2000) Oral acyclovir for herpes simplex virus eye disease: Effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol 118:1030-1036
28. Herpetic Eye Disease Study Group (1998) Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 339:300-306, doi: 10.1056/NEJM199807303390503
29. Martin L (1999) Clinical experience with latanoprost: A retrospective study of 153 patients. Acta Ophthalmol Scand 77:336-339, doi: 10.1034/ j.1600-0420.1999.770318.x
30. DuBiner HB, Mroz M, Shapiro AM, Dirks MS (2001) Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 23:1969-1983, doi: 10.1016/S0149-2918(01)80150-8